Killian Meara

The only pre-exposure prophylaxis approved for twice-a-year dosing, lenacapavir "could be the transformative PrEP option we’ve been waiting for," one expert said.

If the FDA approves the treatment, it will be the first-ever MDMA-assisted therapy and psychedelic-assisted therapy. The PDUFA date is set for August 11, 2024.

Moderna's investigational vaccine against RSV in adults showed mean efficacy of 83% against the infection and is the only mRNA technology-based RSV shot.

The finding implies the potential for virus transmission after initial recovery from the infection, according to study authors.